Aj PakpourFounder, Business Of Modern Medicine · Aj Pakpour | The Business Of Modern Medicine |

The Truth About Retatrutide: What They’re Not Telling You

16 Sept 2026 · 1 min

Watch on YouTube

1:00

Retatrutide, a triple-agonist drug not yet FDA-approved, shows weight loss comparable to bariatric surgery in trials and may beat Ozempic and Mounjaro. People online are already sharing dosing regimens and personal experiences while the drug remains investigational, highlighting how hype outpaces the regulatory process.

Chapters

Retatrutide is becoming America's most talked about weight loss drug, but here is the catch. It isn't FDA approved yet. It's still being studied. Yet somehow it is already everywhere. It is a triple agonist targeting three hormone receptors: GLP-1, GIP, and glucagon. Clinical trials show weight loss comparable to surgery. Outperforming established drugs like Ozempic or Mounjaro. But while those are approved, retatrutide remains investigational, yet demand is exploding across the internet. Social media is full of dosing discussions and people documenting their own unregulated experiences. We are watching what happens when public demand moves faster than traditional drug development. Headlines move at light speed, But science takes time. That is the conversation worth having.